Shares of Flexion Therapeutics, Inc. (NASDAQ:FLXN) have been assigned an average recommendation of “Buy” from the eleven ratings firms that are presently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $33.63.
Several equities analysts have issued reports on FLXN shares. Zacks Investment Research raised Flexion Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, August 28th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $44.00 target price on shares of Flexion Therapeutics in a research report on Thursday, August 10th. ValuEngine raised Flexion Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Needham & Company LLC reaffirmed a “buy” rating and set a $36.00 target price on shares of Flexion Therapeutics in a research report on Sunday, September 17th. Finally, Wells Fargo & Company set a $39.00 price target on Flexion Therapeutics and gave the stock a “buy” rating in a report on Friday.
Shares of Flexion Therapeutics (NASDAQ FLXN) traded up 10.36% during midday trading on Wednesday, reaching $29.93. 8,209,976 shares of the company’s stock were exchanged. Flexion Therapeutics has a 12 month low of $15.93 and a 12 month high of $32.25. The stock’s market cap is $954.92 million. The company’s 50 day moving average is $24.68 and its 200-day moving average is $22.57.
Flexion Therapeutics (NASDAQ:FLXN) last released its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.91) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.80) by ($0.11). Equities analysts forecast that Flexion Therapeutics will post ($3.74) EPS for the current fiscal year.
In other Flexion Therapeutics news, insider Yamo Deniz acquired 3,000 shares of the business’s stock in a transaction dated Friday, September 1st. The shares were purchased at an average cost of $24.15 per share, for a total transaction of $72,450.00. Following the transaction, the insider now owns 5,000 shares in the company, valued at $120,750. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Over the last 90 days, insiders have purchased 5,375 shares of company stock worth $131,575. 15.98% of the stock is owned by corporate insiders.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Fiduciary Trust Co. purchased a new position in Flexion Therapeutics during the second quarter valued at $101,000. IFP Advisors Inc raised its stake in shares of Flexion Therapeutics by 24.5% in the second quarter. IFP Advisors Inc now owns 5,080 shares of the specialty pharmaceutical company’s stock worth $103,000 after purchasing an additional 1,000 shares during the last quarter. Advisor Group Inc. raised its stake in shares of Flexion Therapeutics by 205.9% in the second quarter. Advisor Group Inc. now owns 5,200 shares of the specialty pharmaceutical company’s stock worth $105,000 after purchasing an additional 3,500 shares during the last quarter. Voya Investment Management LLC raised its stake in shares of Flexion Therapeutics by 25.8% in the second quarter. Voya Investment Management LLC now owns 12,914 shares of the specialty pharmaceutical company’s stock worth $261,000 after purchasing an additional 2,651 shares during the last quarter. Finally, BB&T Securities LLC purchased a new position in shares of Flexion Therapeutics in the second quarter worth $289,000. Institutional investors own 83.26% of the company’s stock.
TRADEMARK VIOLATION WARNING: This story was originally reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this story on another domain, it was illegally copied and republished in violation of United States and international copyright & trademark law. The legal version of this story can be accessed at https://www.chaffeybreeze.com/2017/10/07/flexion-therapeutics-inc-flxn-receives-32-50-average-pt-from-brokerages.html.
Flexion Therapeutics Company Profile
Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.
Receive News & Ratings for Flexion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.